Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial - Concepedia

Concepedia

Publication | Open Access

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial

DOI Full Paper Access

47

Citations

37

References

2024

Year

Solange Peters, Byoung Chul Cho, Alexander Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater, Dmytro Trukhin, Sang‐We Kim, G Ursol, Maen Hussein, Farah Louise Lim,

Journal of Thoracic Oncology

References

	Year	Citations

Page 1